GSK and Vir turn to US for distribution as Covid-19 mAb treatment nears blockbuster status
Ever since former President Trump received an infusion of Regeneron’s monoclonal antibody, all three of the now-authorized Covid-19 mAb treatments have been in the spotlight.
The only one flying somewhat under the radar is also the one to most recently receive an emergency authorization, which came last May for GlaxoSmithKline and Vir Biotechnology’s mAb sotrovimab. But that third-to-market status hasn’t stopped the companies from quickly selling about $1 billion worth of doses in the first six months and recently signing a $280 million US government contract.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.